The study is conducted in Asia. The aim of this observational study is to evaluate the weight change from baseline while using Levemir® in subjects with type 2 diabetes mellitus under normal clinical practice conditions in India.
Study Type
OBSERVATIONAL
Enrollment
10,008
Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
Unnamed facility
Bangalore, India
Weight change from baseline
Time frame: after 26 weeks
Number of serious adverse events
Time frame: after 26 weeks
Number of all adverse events
Time frame: after 26 weeks
Number of all hypoglycemic episodes (24 hr, daytime and nocturnal)
Time frame: after 26 weeks
HbA1c change from baseline
Time frame: after 26 weeks
FBG (Fasting Blood Glucose) change from baseline
Time frame: after 26 weeks
Percentage of patients achieving targets of HbA1c less than 7 % and less than 6.5 %
Time frame: after 26 weeks
Insulin dose and frequency at the end of the study
Time frame: after 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.